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Background: There is a lack of feasible and validated measures to self-assess medication adherence for older
patients with stroke. In addition, the potential determinants of medication adherence for older patients with
stroke remain unclear. Objectives: The aims of this study were to (1) examine the psychometric properties of
a 5-item questionnaire on medication adherence, specifically the 5-item Medication Adherence Report Scale
(MARS-5), and (2) explore the determinants of medication adherence. Methods: Stroke patients older than
65 years (N = 523) filled out the MARS-5 and the Hospital Anxiety and Depression Scale. The medication
possession rate (MPR) was calculated to measure the objective medication adherence. Several clinical
characteristics (stroke types, blood pressure, comorbidity, HbA1c, quantity of prescribed drugs, fasting blood
glucose, and total cholesterol) and background information were collected. We used Rasch analysis with a
differential item functioning test to examine psychometric properties. Results: All 5 items in the MARS-5 fit in the
same construct (ie, medication adherence), no differential item functioning items were displayed in the MARS-5
across gender, and the MARS-5 total score was strongly correlated with the MPR (r = 0.7). Multiple regression
models showed that the MARS-5 and the MPR shared several similar determinants. In addition, the variance of the
MARS-5 (R2 = 0.567) was more than that of the MPR (R2 = 0.300). Conclusions: The MARS-5 is a feasible and
valid self-assessed medication adherence for older patients with stroke. In addition, several determinants were
found to be related to medication adherence for older patients with stroke. Healthcare providers may want to
take heed of these determinants to improve medication adherence for this population.
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Stroke is the leading cause of death globally: it is thefifth cause of death in the United States,1 second in
Europe,2 and sixth in Iran.3 Stroke often results in func-
tional disability and has a substantial impact on an
individual"s well-being.4,5 After a person"s first stroke,
the cumulative risk of stroke recurrence is 11.1% after
1 year and 26.4% after 5 years.6 Researchers have
identified 1 cause of recurrence to be medication
nonadherence, because some studies have shown posi-
tive relationships between lower medication adherence
and greater incidences of stroke symptoms.7,8 Guide-
lines for secondary prevention after stroke have explicitly
recommended using appropriate medication to control
or reduce both blood pressure and cholesterol level.9,10
Therefore, promoting medication adherence among
stroke patients is critical, and investigating the poten-
tial determinants for medication adherence among
patients having stroke is important.
Some studies have highlighted the importance of medi-
cation adherence in patients with stroke and investigated
potential determinants. The determinants include beliefs
regarding medications,11,12 low-density lipoprotein
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cholesterol,13 knowledge about medications,14 and a pa-
tient"s emotional state.15 This is to say that positive beliefs
about medications, lower low-density lipoprotein cho-
lesterol, greater knowledge about medications, and less
emotional distress are all positively correlated with better
medication adherence. Although information about these
determinants can help in daily clinical practice, some
knowledge gaps exist regarding whether these determinants
are applicable to older stoke patients in clinical practice.
To the best of our knowledge, no studies have inves-
tigated medication adherence in an older population
with stroke. Given the different characteristics (eg,
healthy literacy and taking polypharmacy treatment
or not) between older and younger stroke patients, the
determinants of medication adherence might be some-
what different between the 2 groups. For example, older
patients may have poorer health literacy (understanding
the importance of each medication and handling adverse
effects), a greater need for polypharmacy treatment
(older patients are more likely to have comorbidities
and need more types of medications than younger
patients), and a need to take more doses each day.16
A review study has identified a variety of potential
factors related to medication adherence,17 and now,
empirical studies are needed to conduct a comprehen-
sive assessment of the determinants for medication
adherence, including demographics, clinical char-
acteristics, and emotional distress. For example, age
and educational level were weakly associated with
adherence for older people.18
Another practical and important issue is to have a
feasible and valid instrument to measure medication
adherence for patients with stroke. A potential candi-
date to assess medication adherence is the Medication
Adherence Report Scale (MARS), which has a 10-item
version (MARS-10) and a 5-item version (MARS-5). The
MARS-10 has been validated for its unidimensionality
among people with mental illness;19,20 however, no
studies have examined the psychometric properties of
MARS-10 in people with stroke. Similarly, we found that
the psychometric evaluation of the MARS-5 has only
been done on populations without stroke using classical
test theory.21Y23 Although some studies have argued
whether the MARS-5 can accurately measure drug
adherence,24,25 other studies have found that the MARS-5
can accurately measure medication adherence.26,27 In
fact, Lin et al28 concluded that the unique characteristics
of different diseases may contribute to different findings
regarding the accuracy of the MARS-5. This highlights
the importance of conducting a psychometric assess-
ment of the MARS-5 in a specific disease population.
We proposed validating the MARS-5 for use in
measuring medication adherence in older patients with
stroke. We chose the MARS-5 over the MARS-10
because the MARS-5 is shorter and will therefore have
a lower administration burden. Although the psycho-
metric properties of the MARS-5 have yet to be
verified in people with stroke, some studies have used
the MARS-5 to assess medication adherence in patients
with stroke.11,12 We will adopt modern test theory (eg,
the Rasch model) to analyze the psychometric proper-
ties of the MARS-5 to fill in the literature gap.
The major benefits of using the Rasch model to test
psychometric properties include the following: (1) it
estimates the person"s ability separately from item
difficulty, so the psychometric results are not sample
dependent; (2) it produces an ordinal-to-interval conver-
sion table based on the probability that a person responds
to a certain answer of an item, and a special unit (ie, logit)
is thus generated with the additive characteristics; and (3)
it helps to identify which item is an unfair item across
subgroups. Differential item functioning (DIF) in the
Rasch model can help us to know whether subgroups
interpret any item with different considerations.29 As
men and women are very likely to have different
thoughts based on different brain structures,30 testing
DIF for MARS-5 across genders is of great interest to
healthcare providers. Specifically, we should identify
whether the score difference of the MARS-5 reflects
the true difference between genders or is due to various
interpretations of the MARS-5.31 Therefore, we claimed
that testing DIF across genders for the MARS-5 is a
prerequisite before clinical application.
The purposes of this study were to examine the
psychometric properties of the MARS-5 in a sample
consisting of elderly patients with stroke and to explore
the determinants of medication adherence in an older
sample with stroke.
Methods
Sampling and Setting
The study participants were stroke patients who had
been discharged from 5 hospitals in Tehran and Qazvin
in 2016. Inclusion criteria were as follows: participants
who (1) had a stroke confirmed by neuroimaging, (2)
were 65 years or older, (3) were responsible to take their
own medication without any help, and (4) had the
ability to read and write in Persian, including the ability
to provide informed consent to participate in the study.
Exclusion criteria were as follows: patients with (1)
moderate to severe cognitive impairment (ie, Mini-
Mental State Examination score G 18) or (2) dysphasia,
aphasia, liver failure, or renal dysfunction. Ethics
approval was obtained from the review committees
of different universities, and all participants were pro-
vided with written informed consent forms.
Measures
Clinical Characteristics
The types of stroke and comorbidity were collected
from patients" medical records. Two research assistants
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measured blood pressures and drew blood for hemo-
globin A1c and lipids. Standard protocol was used to
measure systolic and diastolic blood pressure using
calibrated mercury sphygmomanometers and appropri-
ately sized cuffs. The level of HbA1c, which indicates the
average level of blood glucose levels over 3 months, was
obtained from blood samples and assessed using the
high-pressure liquid chromatography method. Fasting
blood glucose was also assessed using the enzymatic
method. Serum lipid (ie, total cholesterol) was directly
measured using an esterase/oxidase method. Patients"
comorbidity was measured using the Charlson Comor-
bidity Index.
Emotional Distress
The Hospital Anxiety and Depression Scale (HADS)
was used to collect information on emotional distress,
including anxiety and depression performance. The
HADS contains 14 items: 7 items measure anxiety and
another 7 items measure depression using 4 response
categories, where a higher score indicates higher levels
of anxiety or depression.32 The validity of the HADS
has been established in patients with stroke.33 In
addition, the Persian version of the HADS for Iranian
use has satisfactory psychometric properties, including
linguistic validity, internal consistency, known-group
validity, construct validity, and unidimensionality
for each subscale.34,35 In the current study, the internal
consistency was acceptable for the HADS: ! = .83 for
the anxiety subscale and ! = .89 for the depression
subscale.
Medication Adherence
The MARS-5 and medication possession rate (MPR)
were used to observe the medication adherence of
participants. The MARS-5, a self-reported instrument,
contains 5 items regarding medication adherence. Each
item was rated on a 5-point Likert scale, and the range
of the MARS-5 total score is between 5 and 25. A higher
score on the MARS-5 represents better medication
adherence.11,36 In addition, the Persian version of the
MARS-5 for Iranian use has satisfactory internal consis-
tency.37 In the current study, the internal consistency
was acceptable for MARS-5 (! = .85).
The MPR was presented using the number of days
of dispensed medications divided by the total number
of days. Days of dispensed medications were defined
by the number of days on which medications were
dispensed to the participants during the study period.
The total days were defined by the total number of
days in the study period. The calculated values were
then multiplied by 100 and presented as percentages.
All related information was collected monthly from 13
pharmacies among the 5 hospitals in Tehran and
Qazvin and included the total number of pills pre-
scribed along with the dates of each prescription. We
assessed cardiovascular, blood pressureYlowering, and
diabetes medications adjusted for inpatient days and
medication refills before enrollment date, as well as
information on prescription changes registered 2 months
after discharge.
Procedure
Patients with stroke were screened at hospitals for
eligibility by 3 trained physicians. After confirming
eligibility, each participant was asked to sign the
informed consent form and then complete the study
measures including MARS-5 and HADS 2 months
after discharge. The MPR was also calculated 2 months
after discharge. Clinical measures were then collected
2 months after discharge to assess the predictive validity
of the MARS.
Data Analysis
Two statistical programs were used for data analysis:
DIF and Rasch models used WINSTEPS 3.75.0, and
all other analyses used IBM SPSS Statistics 23.0.
Rasch analysis was conducted using a rating scale
model to test the item fit and unidimensionality of the
MARS-5. The item fit was assessed using 2 mean square
(MnSq): the information-weighted fit statistic (infit) and
the outlier-sensitive fit statistic (outfit), in which ranges
between 0.5 and 1.5 suggest that the item is well fit.38,39
Unidimensionality was assessed using principal com-
ponent analysis on the Rasch-retrieved standardized
residuals, in which the first component having an
eigenvalue of less than 2 indicates unidimensionality.29
Person separation reliability reported by the Rasch
analysis should be less than 0.7 to indicate adequate
consistency in the MARS-5.40 The Likert-type scale of
the MARS-5 was examined for its categorical func-
tioning: successive responses for each item score are
located in their expected orders. Specifically, the
average difficulty of the scores and score thresholds
(the thresholds between every 2 scores) should both
increase monotonically with the scores.41 Differential
item functioning analysis was conducted to investigate
whether male and female stoke patients interpret the
MARS-5 differently. A substantial DIF item indicates
that the item description has different difficulties for
different subgroups of respondents (different genders
in this study).42 We adopted the usual method to
identify DIF items: a DIF contrast (ie, the difference of
difficulty between 2 groups) of greater than 0.5 suggests
a substantial DIF.43
We examined the relationship between MARS-5
and the MPR using the Pearson correlation coeffi-
cient. Afterward, we constructed 2 regression models
to explore the factors for medication adherence mea-
sured by the MARS-5 and MPR, respectively. We used a
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total score of the MARS-5 and MPR as 2 dependent
variables. Demographic variables (age, gender, marital
status, monthly family income, and educational level),
clinical characteristics (comorbidity, fasting blood
glucose test, blood pressure, total cholesterol, and
HbA1c), and emotional distress (anxiety and depres-
sion) were used as independent variables. All the
continuous variables (age, fasting blood glucose test,
blood pressure, total cholesterol, HbA1c, and emo-
tional distress) could be viewed as normally distrib-
uted. The multicollinearity among the independent
variables was acceptable.
Our final sample size (N = 523) was sufficient for all
our analyses. The required sample size for Rasch to
achieve a stable estimate is 250,44 especially for a
questionnaire using a 5-point Likert-type scale such as
the MARS-5. In terms of regression analyses, Austin
and Steyerberg45 suggested that each variable needs
15 to 25 participants. Given that we used 13 variables
in each regression model, the sample size fell between
195 and 325.
Results
Table 1 presents the demographic information, clinical
characteristics, emotional distress performance, and
medication adherence for the participants (N = 523).
The Rasch analysis showed that the MARS-5 had
satisfactory item properties: infit MnSq of 0.74 to 1.25
and outfit MnSq of 0.68 to 1.40. The first eigenvalue
of the principal component analysis on the standard-
ized residuals was 1.6, which suggests unidimension-
ality of the MARS-5. The Person separation reliability
of the MARS-5 was adequate (0.74). The categorical
functioning of the rating scale in the MARS-5 was
within the anticipated monotonic increment: the
average difficulties were j6.16 for score 1, j0.28 for
score 2, 2.92 for score 3, 4.92 for score 4, and 6.57 for
score 5. The score thresholds were monotonically
increased: j9.01 from scores 1 to 2, j0.01 from
scores 2 to 3, 3.76 from scores 3 to 4, and 5.27 from
scores 4 to 5. No substantial DIF items were displayed
across genders because all the absolute DIF contrasts
were less than 0.5 (see Table 2).
The correlation between the MARS-5 total score and
the MPR was strong (r = 0.70, P G .001). In the model
with the MARS-5 as a dependent variable, gender,
marital status, monthly family income, and all the
clinical characteristics were significant predictors. In
the MPR model, gender, monthly family income, and
all clinical characteristics except comorbidity and
HbA1c were significant predictors. Anxiety was signif-
icantly associated with the MARS-5 but not with the
MPR, whereas depression was significantly associated
with the MPR but not with the MARS-5. In addition,
female gender, fair to good monthly family income
(9$500), and a higher quantity of prescribed drugs were
associated with higher MARS-5 and/or MPR scores.
Unmarried status; the presence of comorbidities; higher
levels of fasting blood glucose, blood pressure, total
cholesterol, and HbA1c; anxiety; and depression were
associated with lower MARS-5 and/or MPR scores
(see Table 3). Because the model using the MARS-5 as a
dependent variable had more significant predictors than
the model using the MPR as a dependent variable, the
former model (R2 = 0.567) explained more variance
than did the latter (R2 = 0.300).
Discussion
Our psychometric findings demonstrate that the
MARS-5 is a valid measure to assess medication
adherence in older patients with stroke. Based on the
satisfactory results of the Rasch analysis and a high
correlation with the MPR (r = 0.7), the MARS-5
may be a useful instrument for clinicians and re-
searchers to measure medication adherence. We extended
knowledge about the psychometric properties of the
MARS-5 from classic test theory findings to Rasch
analysis, including DIF across genders. That is, all the
TABLE 1 Participant Characteristics (N = 523)
Mean (SD)
or n (%)
Demographic information
Age, y 72.9 (6.5)
Gender (male) 220 (42.1)
Marital status (living with a spouse) 417 (79.7)
Educational level
No formal/primary school 108 (20.7)
Primary school 170 (32.5)
Secondary school or higher 245 (46.8)
Monthly family income
Poor ($0Y$500) 189 (36.1)
Fair ($500Y$1000) 310 (59.3)
Good (9$1000) 24 (4.6)
Clinical characteristics
Diagnosis
Ischemic stroke 377 (72.1)
Transient ischemic stroke 108 (20.7)
Intracerebral hemorrhage 38 (7.3)
Comorbidity (yes) 256 (48.9)
Fasting blood glucose test, mg/dL 142.92 (67.49)
HbA1c 7.23 (1.32)
Systolic blood pressure, mm Hg 127.26 (14.98)
Diastolic blood pressure, mm Hg 77.46 (9.31)
Total cholesterol, mg/dL 180.53 (78.09)
No. prescribed drugs 3.4 (1.8)
Emotional distressa
Anxiety 11.2 (4.1)
Depression 10.1 (4.4)
Medication adherence
5-Item Medication Adherence Report Scale 21.6 (3.3)
Medication possession rate 61.6 (19.1)
aMeasured using the Hospital Anxiety and Depression Scale.
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MARS-5 items are invariant across genders: male and
female patients interpreted the 5 items similarly
without substantial DIF, and the items have the same
meanings for both genders.
The unidimensionality of the MARS-5 is in agreement
with another study on children and their caregivers.21
Although no studies have used Rasch analysis on the
MARS-5, our results are comparable with the findings
of 2 recent studies that applied Rasch analysis to the
MARS-10 in people with mental illness.19,20 All of their
findings and ours in fit statistics were satisfactory: infit
MnSq ranged between 0.74 and 1.25 in our study,
between 0.90 and 1.03 in Fond et al,19 and between
0.92 and 1.03 in Zemmour et al.20
There has been a debate as to whether the MARS-5 is
an appropriate measure for medication adherence24Y27
and whether different characteristics of disease patients
may affect the accuracy of the MARS-5.28 Based on
our rigorous psychometric findings (unidimensionality
of the MARS-5, no DIF items in the MARS-5, and a
TABLE 2 Rasch Analysis on the 5-Item Medication Adherence Report Scale (N = 523)
Item No.: Content Difficulty Infit MnSq
Outfit
MnSq
Difficulty
for Men
Difficulty for
Women DIF Contrast
Item 1: change dosage 0.00 0.95 0.87 0.07 j0.05 0.12
Item 2: forget to take 1.78 1.25 1.40 2.02 1.59 0.43
Item 3: stop taking j1.18 1.12 1.06 j1.15 j1.22 0.07
Item 4: skip one of the
dosages
0.05 0.87 0.83 j0.22 0.24 j0.46
Item 5: take less than
prescribed
j0.65 0.74 0.68 j0.81 j0.54 j0.27
DIF contrast indicates the difficulty for men minus difficulty for women (positive values imply more difficult for men, and negative values imply more
difficult for women). Acceptable infit and outfit MnSq is between 0.5 and 1.5; acceptable DIF contrast is less than 0.5.
Abbreviations: DIF, differential item functioning; MnSq, mean square.
TABLE 3 Multiple Linear Regression Models on the 5-Item Medication Adherence Report Scale and
Medication Possession Rate (N = 523)
MARS-5 MPR
Coefficient
Standard
Error
Standardized
Coefficient P Coefficient
Standard
Error
Standardized
Coefficient P
Demographics
Age, y j0.02 0.02 j0.04 .23 j0.18 0.12 j0.06 .16
Female gender
(reference: male)
0.59 0.22 0.09 .01 3.39 1.60 0.09 .03
Secondary school or
higher (reference:
eprimary)
j0.14 0.30 j0.02 .64 1.22 2.23 0.03 .58
Currently unmarried
(reference: married)
j0.88 0.34 j0.11 .01 j3.80 2.49 j0.08 .13
Fair and good
socioeconomic status
(reference: poor)
0.68 0.24 0.10 .01 4.55 1.78 0.11 .01
Clinical characteristics
No. prescribed drugs 0.43 0.08 0.22 G.001 2.05 0.57 0.19 G.001
Comorbidity j0.60 0.25 j0.09 .02 j1.12 1.84 j0.03 .55
Fasting blood glucose
test, mg/dL
j0.02 0.00 j0.48 G.001 j0.10 0.01 j0.35 G.001
Mean arterial pressure,
mm Hg
j0.08 0.01 j0.24 G.001 j0.40 0.08 j0.22 G.001
Total cholesterol, mg/dL j0.01 0.00 j0.16 G.001 j0.02 0.01 j0.10 .02
HbA1c j0.35 0.10 j0.14 G.001 j0.68 0.72 j0.05 .34
Emotional distress
Anxietya j0.12 0.04 j0.15 .003 0.15 0.29 0.03 .60
Depressiona j0.04 0.04 j0.05 .30 j0.66 0.28 j0.15 .02
Model statistics
F (P) 46.40 (G.001) 15.07 (G.001)
Degrees of freedom 13, 460 13, 460
R2 (adjusted R2) 0.567 (0.555) 0.300 (0.280)
Significant coefficients are in bold.
Abbreviations: MARS-5, 5-item Medication Adherence Report Scale; MPR, medication possession rate.
aMeasured using the Hospital Anxiety and Depression Scale.
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high correlation with the MPR), we are confident that
the MARS-5 is able to accurately measure medication
adherence for older patients with stroke. Nonetheless,
future studies are warranted to corroborate with our
findings because this is only the first study to inves-
tigate the psychometric properties of the MARS-5 on
patients with stroke.
Another important issue in psychometric properties
for the MARS-5 is the DIF across genders. Different
subgroups are likely to interpret item contents differ-
ently, especially subgroups that usually have different
perspectives, such as the gender subgroups we tested in
this study. To fairly assess item scores across subgroups,
DIF should be tested before combining or comparing
the subgroups" scores.42 Because no DIF items were
displayed, combining or comparing the MARS-5 scores
of older male and female stroke patients is acceptable.
Based on the sound psychometric properties, we
further investigated possible determinants for medica-
tion adherence in older patients with stroke. The
associations between demographic variables and med-
ication adherence in our regression model were similar
to the findings of 2 review studies: female gender, living
with a spouse, and high monthly family income are
correlated with increased compliance; age and educa-
tional level are weakly associated with adherence, espe-
cially for older people.17,18 In addition, similar to the
findings of Phillips et al,15 our regression model dem-
onstrated that emotional distress was negatively corre-
lated to good medication adherence.
In terms of clinical characteristics, we found that,
when the patients had higher scores on the Charlson
Comorbidity Index, their medication adherence was
poorer. The findings of clinical characteristics are
somewhat similar to the study of Cummings et al,7 in
which blood pressure was positively correlated with
medication adherence in hypertension patients. Our
other clinical characteristics indicated that poor medi-
cation adherence existed in stroke patients who had a
higher risk of diabetes mellitus. Diabetes mellitus is
highly correlated with stroke,46 and stroke patients are
highly likely to have recurrence,6 so clinicians may
want to pay additional attention to these significant
clinical characteristics for patients with stroke. Our
findings also correspond to the guidelines that suggest
controlling blood pressure and cholesterol level.9,10
There are some limitations in the study. First, fewer
than 10% of our participants were diagnosed with
intracerebral hemorrhage, and our results may not
be able to generalize to patients with this type of stroke.
Second, the study only recruited patients from 5 hospitals
in Tehran and Qazvin; thus, the generalizability of our
study results might not be applicable throughout Iran.
Third, because our sample was Iranian without moderate
to severe cognitive impairment, our results are unable to
generalize to stroke patients in other countries or those
with cognitive impairment. Fourth, our results might be
influenced by the different stroke types in our study.
Specifically, the pathophysiologic mechanisms between
transient ischemic stroke, ischemic stroke, and hemor-
rhagic stroke are quite different. These different mecha-
nisms might affect the medication adherence of patients
with stroke at different levels. Therefore, future studies
using a homogeneous sample in stroke type (eg, transient
ischemic stroke) and diversity in other populations (eg,
Westerners and Asians) are warranted to corroborate
our findings. Moreover, future research should consider
measuring the functional status of the patients.
Conclusions
The MARS-5 has satisfactory psychometric properties
according to the Rasch model. The results indicate that
the scale is unidimensional, the response scale (ie, the
5-point Likert-type scale) functions appropriately,
the targeting is acceptable, and no DIF items were
displayed across genders. Thus, the MARS-5 might
be a useful measure for both clinicians and researchers
to assess medication adherence.
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